SIGLEC1 and neoplasm: Our recent work confirmed this hypothesis (8) and in this study we took advantage of this property to purify SSMs from tumor-draining lymph nodes (tdLNs) as 7AAD– CD45+ CD3– B220– Ly6G– CD11b+ CD169+ CD11c– SSCLO (Figure 1A).